Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

lebrikizumab

A humanized monoclonal antibody against interleukin 13 (IL-13) with immunosuppressive and anti-asthmatic activities. Lebrikizumab binds to IL-13 and inhibits IL-13-mediated pathways. IL-13, a cytokine mainly secreted by type 2 helper T cells, plays a key role in the induction of allergic inflammation.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	anti-IL-13 humanized monoclonal antibody TNX-650 immunoglobulin G4, anti-(human interleukin 13) (human-mouse monoclonal MILR1444a gamma-4-chain), disulfide with human-mouse monoclonal MILR1444a kappa-chain, dimer monoclonal antibody TNX-650
Abbreviation:	TNX-650
Code name:	MILR1444A PRO301444

lebrikizumab

Search NCI's Drug Dictionary